|
Sign In to gain access to subscriptions and/or personal tools.
|
Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy
Willemijn AKM Windt
Department of Clinical Pharmacology, Groningen Institute for Drug Evaluation (GUIDE), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Atsua Tahara
Institute for Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan
Alex CA Kluppel
Department of Clinical Pharmacology, Groningen Institute for Drug Evaluation (GUIDE), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Dick de Zeeuw
Department of Clinical Pharmacology, Groningen Institute for Drug Evaluation (GUIDE), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Robert H Henning
Department of Clinical Pharmacology, Groningen Institute for Drug Evaluation (GUIDE), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Richard PE van Dokkum
Department of Clinical Pharmacology, Groningen Institute for Drug Evaluation (GUIDE), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, r.p.e.van.dokkum{at}med.umcg.nl
Introduction. Vasopressin, mainly through the V1a-receptor, is thought to be a major player in the maintenance of hyperfiltration. Its inhibition could therefore lead to a decrease in progression of chronic renal failure.To this end, the effect of the vasopressin V1a-receptor-selective antagonist, YM218, was studied on proteinuria and focal glomerulosclerosis in early and late intervention after 5/6 nephrectomy in rats, and compared with an angiotensin-converting enzyme inhibitor (ACE-I).
Materials and methods. After 5/6 nephrectomy, early intervention was performed between week 2 and 10 thereafter with the V1a-receptor-selective antagonist (VRA, 10 mg/kg/day, n=10), enalapril (ACE-I, 10 mg/kg/day, n=9), or vehicle (n=8). Late intervention was performed in another group between week 6 and 12 with VRA (10 mg/kg/day, n=7), lisinopril (ACE-I, 5 mg/kg/day, n=7), or vehicle (n=7).
Results. In early intervention, proteinuria and focal glomerulosclerosis were significantly decreased by VRA compared to vehicle (44 7% and 59+8% respectively). ACE-I significantly decreased proteinuria (67 7%) and a trend towards a decrease in focal glomerulosclerosis was observed (30 18%). In late intervention, VRA did not decrease proteinuria and focal glomerulosclerosis compared to vehicle (21 20% and 0%, respectively),ACE-I significantly lowered proteinuria (92 2%) and a focal glomerulosclerosis (69+1%) lowering trend was observed.
Conclusion. These results indicate that VRA may protect against early progression of renal injury after 5/6 nephrectomy, whereas its effectiveness seems limited in established renal damage.
Key Words: 5/6 nephrectomy • ACE-inhibition • glomerular hyperfiltration • focal glomerulosclerosis • proteinuria • vasopressin antagonism
References
- Naitoh M.I., Suzuki H., Murakami M. et al. Effects of oral AVP receptor antagonists H, OPC-21268 and OPC-31260 of on AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994; 267(6Pt2):H2245-H2254.[Web of Science][Medline]
[Order article via Infotrieve]
- Bardoux P., Martin H., Ahloulay M. et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci USA 1999;96:10397-402.[Abstract/Free Full Text]
- Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001;51:372-90.[Abstract/Free Full Text]
- Bouby N., Bachmann S., Bichet D., Bankir L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990;258(4Pt2): F973-F979.[Web of Science][Medline]
[Order article via Infotrieve]
- Edwards RM, Trizna W., Kinter LB Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989;256(2Pt2):F274-F278.[Web of Science][Medline]
[Order article via Infotrieve]
- Ganz MB, Pekar SK, Perfetto MC, Sterzel RB Arginine vasopressin promotes growth of rat glomerular mesangial cells in culture. Am J Physiol 1988;255(5Pt2):F898-F906.[Web of Science][Medline]
[Order article via Infotrieve]
- Roald AB, Tenstad O., Aukland K. The effect of AVP-V receptor stimulation on local GFR in the rat kidney. Acta Physiol Scand 2004;182:197-204.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Harrison-Bernard LM, Carmines PK Juxtamedullary microvascular responses to arginine vasopressin in rat kidney. Am J Physiol 1994;267(2Pt2):F249-F256.[Web of Science][Medline]
[Order article via Infotrieve]
- Cavarape A., Bauer J., Bartoli E., Endlich K., Parekh N. Effects of angiotensin II, arginine vasopressin and thromboxane A2 in renal vascular bed: role of rho-kinase. Nephrol Dial Transplant 2003;18:1764-9.[Abstract/Free Full Text]
- Okada H., Suzuki H., Kanno Y., Saruta T. Effects of novel, nonpeptide vasopressin antagonists on progressive nephrosclerosis in rats. J Cardiovasc Pharmacol 1995;25:847-52.[Web of Science][Medline]
[Order article via Infotrieve]
- Okada H., Suzuki H., Kanno Y., Saruta T. Evidence for the involvement of vasopressin in the pathophysiology of adriamycin-induced nephropathy in rats. Nephron 1996; 72:667-72.[Web of Science][Medline]
[Order article via Infotrieve]
- Tahara A., Tsukada J., Tomura Y. et al. Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res 2005;51:275-81.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Marcel de Vries PA, Navis G., De Boer E., De Jong PE, De Zeeuw D. A method for accurate measurement of GFR in conscious, spontaneously voiding rats. Kidney Int 1997;52:244-7.[Web of Science][Medline]
[Order article via Infotrieve]
- Tsukada J., Tahara A., Tomura Y. et al. Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V(1A) receptor-selective antagonist. Vascul Pharmacol 2005;42:47-55.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bos H., Laverman GD, Henning RH et al. Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats. JRAAS 2003;4:106-12.[Medline]
[Order article via Infotrieve]
- Wapstra FH, Navis GJ, Van Goor H. et al. ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy. Exp Nephrol 2001;9(1):21-7.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kocks MJ, Gschwend S., De Zeeuw D., Navis G., Buikema H. Low sodium modifies the vascular effects of angiotensin-converting enzyme inhibitor therapy in healthy rats. J Pharmacol Exp Ther 2004;310:1183-9.[Abstract/Free Full Text]
- Brooks DP, Solleveld HA, Contino LC Vasopressin and the pathogenesis of chronic renal failure. Br J Pharmacol 1990;100(1):79-82.[Web of Science][Medline]
[Order article via Infotrieve]
- Yoshida Y., Kawamura T., Ikoma M., Fogo A., Ichikawa I. Effects of antihypertensive drugs on glomerular morphology. Kidney Int 1989;36:626-35.[Web of Science][Medline]
[Order article via Infotrieve]
- Maschio G., Marcantoni C., Bernich P. Lessons from large interventional trials on antihypertensive therapy in chronic renal disease. Nephrol Dial Transplant 2002;17(suppl) 11:47-9.[Free Full Text]
- Tahara A., Tsukada J., Tomura Y. et al. Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells. Eur J Pharmacol 2006;538(1-3):32-8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Nonoguchi H., Takayama M., Owada A. et al. Role of urinary arginine vasopressin in the sodium excretion in patients with chronic renal failure. Am J Med Sci 1996;312:195-201.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bardoux P., Bichet DG, Martin H. et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003;18:497-506.[Abstract/Free Full Text]
- Griffin KA, Picken M., Bidani AK Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 1994;4:2023-31.[Abstract]
- Griffin KA, Picken MM, Churchill M., Churchill P., Bidani AK Functional and structural correlates of glomerulosclerosis after renal mass reduction in the rat. J Am Soc Nephrol 2000;11:497-506.[Abstract/Free Full Text]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 4,
217-224 (2006)
DOI: 10.3317/jraas.2006.041
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Dutertre, D. Croker, N. L. Daly, A. Andersson, M. Muttenthaler, N. G. Lumsden, D. J. Craik, P. F. Alewood, G. Guillon, and R. J. Lewis
Conopressin-T from Conus tulipa Reveals an Antagonist Switch in Vasopressin-like Peptides
J. Biol. Chem.,
March 14, 2008;
283(11):
7100 - 7108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
